Lilly’s New Anti-Amyloid Play Hinges On Tau Bet

Redesigned Phase III Trial May Confirm Phase II Donanemab Results

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

TRAILBLAZER-ALZ met the primary, but not most secondary endpoints. Lilly said efficacy of its amyloid-clearing agent depends on tau levels at baseline and reductions in some parts of the brain.

Poker chips on red background
Lilly's bet on donanemab depends on tau levels and tau burden reductions • Source: Shutterstock

Eli Lilly and Company is no stranger to the risky business of Alzheimer’s disease drug development, which may be why the big pharma is willing to place a high-risk bet on its newest amyloid-clearing therapy donanemab based on mixed results in the Phase II TRAILBLAZER-ALZ clinical trial. The company is converting its ongoing Phase IIb TRAILBLAZER-ALZ2 trial into a Phase III study, upping the number of patients and changing the endpoint to make its wager on donanemab a safer bet.

Lilly presented detailed results from TRAILBLAZER-ALZ during the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) and the data simultaneously...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D